Wednesday, October 5, 2011

Gilead strikes licensing deal with Boehringer Ingelheim on new HIV drug

Gilead Sciences Inc. will license HIV-fighting drugs from Boehringer Ingelheim, including one early-stage treatment.
The deal includes an upfront payment, which Foster City-based Gilead (NASDAQ: GILD) did not disclose, and additional development, regulatory and commercial milestone payments.

No comments:

Post a Comment